E-LIB Suche - Ergebnisse für: Thuluva, Subhash

1

Immunogenicity and safety of a 14-valent pneumococcal polys..:

Matur, Ramesh V. ; Thuluva, Subhash ; Gunneri, Subbareddy...
Vaccine. 42 (2024) 13 - p. 3157-3165 , 2024

2

A phase II/III randomised, comparative study evaluating the..:

Thuluva, Subhash ; Gunneri, SubbaReddy ; Turaga, Kishore...
Contemporary Clinical Trials Communications. 36 (2023) - p. 101232 , 2023

Link: https://doi.org/10.1016/..

3

Immunogenicity and safety of Biological E's CORBEVAX™ vacci..:

Thuluva, Subhash ; Paradkar, Vikram ; Gunneri, SubbaReddy...
Human Vaccines & Immunotherapeutics. 19 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

4

Evaluation of safety and immunogenicity of receptor-binding..:

Thuluva, Subhash ; Paradkar, Vikram ; Gunneri, Subba Reddy...
eBioMedicine. 83 (2022) - p. 104217 , 2022

Link: https://doi.org/10.1016/..

5

Safety, tolerability and immunogenicity of Biological E's C..:

Thuluva, Subhash ; Paradkar, Vikram ; Gunneri, SubbaReddy...
Vaccine. 40 (2022) 49 - p. 7130-7140 , 2022

Link: https://doi.org/10.1016/..

6

A multicenter, single-blind, randomized, phase-2/3 study to..:

Thuluva, Subhash ; Paradkar, Vikram ; Matur, Ramesh..
Human Vaccines & Immunotherapeutics. 18 (2022) 5 - p. , 2022

Link: https://doi.org/10.1080/..

7

A single blind randomized phase 3 study to evaluate safety ..:

Thuluva, Subhash ; Matur, Ramesh ; TSA, Kishore.
Vaccine. 39 (2021) 49 - p. 7166-7174 , 2021

Link: https://doi.org/10.1016/..

8

A multi-center, randomized, controlled, phase-2/3 study to ..:

Thuluva, Subhash ; Turaga, Kishore ; G. V., Subba Reddy...
https://www.ijclinicaltrials.com/index.php/ijct/article/view/676/380. , 2023

Link: https://www.ijclinicaltr..

9

A phase II/III randomised, comparative study evaluating the..:

Thuluva, Subhash ; Gunneri, SubbaReddy ; Turaga, Kishore...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696430/. , 2023

Link: http://www.ncbi.nlm.nih...

10

Immunogenicity and safety of Biological E's CORBEVAX™ vacci..:

Thuluva, Subhash ; Paradkar, Vikram ; Gunneri, SubbaReddy...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294721/. , 2023

Link: http://www.ncbi.nlm.nih...

11

A multicenter, single-blind, randomized, phase-2/3 study to..:

Thuluva, Subhash ; Paradkar, Vikram ; Matur, Ramesh..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196756/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Responders and Non-responders to the therapy of Hypercholes..:

Thuluva, Subhash Chandra
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:5N-07370. , 2006

Link: https://hdl.handle.net/2..

13

Immunogenicity and safety of Biological E's CORBEVAX™ vacci..:

Subhash Thuluva ; Vikram Paradkar ; SubbaReddy Gunneri...
http://dx.doi.org/10.1080/21645515.2023.2203632. , 2023

Link: https://doi.org/10.1080/..

14

A phase II/III randomised, comparative study evaluating the..:

Subhash Thuluva ; SubbaReddy Gunneri ; Kishore Turaga...
http://www.sciencedirect.com/science/article/pii/S2451865423001783. , 2023

Link: https://doi.org/10.1016/..

15

Evaluation of safety and immunogenicity of receptor-binding..:

Subhash Thuluva ; Vikram Paradkar ; Subba Reddy Gunneri...
http://www.sciencedirect.com/science/article/pii/S2352396422003991. , 2022

Link: https://doi.org/10.1016/..